The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description

Louise M. Paterson, Remy S.A. Flechais, Anna Murphy, Laurence J. Reed, Sanja Abbott, Venkataramana Boyapati, Rebecca Elliott, David Erritzoe, Karen D. Ersche, Yetunde Faluyi, Luca Faravelli, Emilio Fernandez-Egea, Nicola J. Kalk, Shankar S. Kuchibatla, John McGonigle, Antonio Metastasio, Inge Mick, Liam Nestor, Csaba Orban, Filippo PassettiEugenii A. Rabiner, Dana G. Smith, John Suckling, Roger Tait, Eleanor M. Taylor, Adam D. Waldman, Trevor W. Robbins, Jf William Deakin, David J. Nutt*, Anne R. Lingford-Hughes

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    26 Citations (SciVal)
    Original languageEnglish
    Pages (from-to)943-960
    Number of pages18
    JournalJournal of Psychopharmacology
    Volume29
    Issue number9
    DOIs
    Publication statusPublished (VoR) - 23 Sept 2015

    Keywords

    • Addiction
    • dopamine D3 receptor
    • functional magnetic resonance imaging
    • neurokinin 1 receptor
    • μ-opioid receptor

    Fingerprint

    Dive into the research topics of 'The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description'. Together they form a unique fingerprint.

    Cite this